Qiagen NV (LTS:0RLT)
€ 43.54 0 (0%) Market Cap: 9.16 Bil Enterprise Value: 9.58 Bil PE Ratio: 106.36 PB Ratio: 2.73 GF Score: 85/100

Qiagen NV at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 13, 2021 / 01:30PM GMT
Release Date Price: €46.51 (-4.08%)
Michael Klaus Jungling
Morgan Stanley, Research Division - MD, Head of MedTech & Services and Analyst

So a warm welcome to another virtual fireside chat at the Morgan Stanley Global Healthcare Conference. I'm delighted to have QIAGEN with us today, a leader in molecular diagnostics. My name is Mike Jungling, and I'll be a moderator for this session. We have 30 minutes for this call. (Operator Instructions) I've been asked by our compliance department to quickly mention a couple of disclaimers.

And here I go. This webcast is not for members of the press. If you are members of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley website, which is www.morganstanley.com/researchdisclosures. And if you have any questions, please contact your sales representative.

It's now with good pleasure to introduce Roland Sackers, CFO of QIAGEN, but we also have with us today John Gilardi, VP of Investor Relations. And with this, I would like to hand

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot